Doxorubicin-resistant, MRP1-expressing U-1285 cells are sensitive to idarubicin

Therapeutic Drug Monitoring

Volumn 25, Issue 3, 2003, Pages 331-339

  Jönsson Videsäter, Kerstin ^a   Andersson, Göran ^a   Bergh, Jonas ^a   Paul, Christer ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Buthionine sulphoximine; Cytotoxicity; Daunorubicin; Doxorubicin; Idarubicin; MRP1; Multidrug resistance; SCLC; U 1285; Verapamil

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORODEOXYADENOSINE; CYTARABINE; DAUNORUBICIN; DEMETHOXYDAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; MELPHALAN; MESSENGER RNA; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL STRAIN; CELL STRAIN U 1285; CYTOTOXICITY; DRUG ACCUMULATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AREA UNDER CURVE; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; IDARUBICIN; RNA, MESSENGER;

EID: 18744430457     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200306000-00014     Document Type: Article

References (45)

1. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
2. van Zuylen L, Nooter K, Sparreboom A, et al. Development of multidrug-resistance convertors: sense or nonsense? Invest New Drugs 2000;18:205-20.
3. Withoff S, de Vries EG, Keith WN, et al. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer 1996;74:1869-76.
4. Scheffer GL, Wijngaard PL, Flens MJ, et al. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995;1:578-82.
5. Scheffer GL, Maliepaard M, Pijnenborg AC, et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res 2000;60:2589-93.
6. Grant CE, Valdimarsson G, Hipfner DR, et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54:357-61.
7. Keppler D, Leier I, Jedlitschky G, et al. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. Chem Biol Interact 1998;111-112:153-61.
8. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997;57:3537-47.
9. Kool M, van der Linden M, de Haas M, et al. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res 1999;59:175-82.
10. Aszalos A, Ross DD. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. Anticancer Res 1998;18:2937-44.
11. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998;16:3674-90.
12. Kruh GD, Gaughan KT, Godwin A, et al. Expression pattern of MRP in human tissues and adult solid tumor cell lines. J Natl Cancer Inst 1995;87:1256-8.
13. Legrand O, Perrot JY, Tang R, et al. Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. Br J Haematol 1996;94:23-33.
14. Bergh J, Larsson E, Zech L, et al. Establishment and characterization of two neoplastic cell lines (U-1285 and U-1568) derived from small cell carcinoma of the lung. APMIS 1982;90:149-58.
15. Davies SL, Bergh J, Harris AL, et al. Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors. Br J Cancer 1997;75:816-21.
16. Batist G, Schecter R, Woo A, et al. Glutathione depletion in human and in rat multidrug resistant breast cancer cell lines. Biochem Pharmacol 1991;41:631-5.
17. Grech KV, Davey RA, Davey MW. The relationship between modulation of MDR and glutathione in MRP-overexpressing human leukemia cells. Biochem Pharmacol 1998;55:1283-9.
18. Jönsson K, Dahlberg N, Tidefelt U, et al. Characterization of an anthracycline-resistant human promyelocyte leukemia (HL-60) cell line with an elevated MDR-1 gene expression. Biochem Pharmacol 1995;49:755-62.
19. Rhedin AS, Tidefelt U, Jönsson K, et al. Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells. Leuk Res 1993;17:271-6.
20. Sundman-Engberg B, Tidefelt U, Liliemark J, et al. Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo. Cancer Chemother Pharmacol 1990;25:252-6.
21. Tidefelt U, Sundman-Engberg B, Rhedin AS, et al. In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations. Eur J Haematol 1989;43:374-84.
22. Davey MW, Hargrave RM, Davey RA. Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells. Leuk Res 1996;20:657-64.
23. Lowry OM, Rosenbrough NJ, Farr AL, et al. Protein measurement with Folin phenol reagent. J Biol Chem 1951;193:265-75.
24. Legrand O, Simonin G, Perrot JY, et al. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998;91:4480-8.
25. Zaman GJ, Versantvoort CH, Smit JJ, et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 1993;53:1747-50.
26. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR 1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A 1990;87:7160-4.
27. Paul C, Peterson C, Gahrton G, et al. Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells. Cancer Chemother Pharmacol 1979;2:49-52.
28. Almquist KC, Loe DW, Hipfner DR. et al. Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell. Cancer Res 1995;55:102-10.
29. Loe DW, Deeley RG, Cole SP. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996;32A:945-57.
30. Nooter K, de la Riviere GB, Klijn J, et al. Multidrug resistance protein in recurrent breast cancer. Lancet 1997;349:1885-6.
31. Kuss BJ, Deeley RG, Cole SP, et al. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet 1994;343:1531-4.
32. Dohner K, Schlenk RF, van der Reijden BA, et al. Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact. Leukemia 2000;14:1154.
33. van Der Kolk DM, Vellenga E, van Der Veen AY, et al. Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity. Blood 2000;95:3514-9.
34. Fardel O, Laupeze B, Amiot L, et al. High multidrug resistance-associated protein (MRP) activity in acute myeloid leukemias is associated with poor response to chemotherapy and reduced patient survival. Presented at the American Society of Hematology 43rd Annual Meeting and Exposition, Orlando, FL, 2001.
35. Schneider E, Cowan KH, Bader H, et al. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995;85:186-93.
36. Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995;9:1661-6.
37. Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biologic and clinical implications. Br J Haematol 1999;104:328-35.
38. Binaschi M, Supino R, Gambetta RA, et al. MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. Int J Cancer 1995;62:84-9.
39. Cole SP. Patterns of cross-resistance in a multidrug-resistant small cell lung carcinoma cell line. Cancer Chemother Pharmacol 1990;26:250-6.
40. Mirski SE, Gerlach JH, Cole SP. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 1987;47:2594-8.
41. den Boer ML, Pieters R, Kazemier KM, et al. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia. Leukemia 1998;12:912-20.
42. Cole SP, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 1998;20:931-40.
43. Shrieve DC, Harris JW. Effects of glutathione depletion by buthionine sulfoximine on the sensitivity of EMT6/SF cells to chemotherapy agents or X radiation. Int J Radiat Oncol Biol Phys 1986;12:1171-4.
44. Fukushima T, Inoue H, Takemura H, et al. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin. Leuk Res 1998;22:625-9.
45. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992;79:3267-73.